INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Paper

Risk Assessment and Management Tools in QA

Balli Rathod*, Harshal Navale, Dr. Sachin Datkhile

Samarth Institute of Pharmacy, Belhe

ARTICLE INFO

Published: 28 May 2025
Keywords:
Risk Assessment, Risk Management Tools, Pharmaceutical Supply Chain, Quality Risk Management (QRM), Pharmaceutical Manufacturing Risks.
DOI:
10.5281/zenodo.15537538

ABSTRACT

Risk assessment and management are crucial for guaranteeing the efficacy, safety, and quality of pharmaceuticals. As regulatory scrutiny intensifies and pharmaceutical processes grow more complex, it is essential to incorporate strong risk management strategies into Quality Assurance (QA). The evolution of the industry necessitates proactive risk management approaches to reduce deviations, maintain compliance, and protect public health. Important conventional methods, such as Fault Tree Analysis (FTA), Hazard Analysis and Critical Control Points (HACCP), and Failure Mode and Effects Analysis (FMEA). Examined for their effectiveness in recognizing, evaluating, and reducing risks throughout different phases of the product lifecycle. Furthermore, Innovative technologies like the Internet of Things (IoT), machine learning (ML), and artificial intelligence (AI) are examined for their ability to transform risk prediction and facilitate real-time tracking of essential quality metrics. Particular focus is placed on new therapeutic fields like biologics, biosimilars, and personalized medicine, which present distinct risk management challenges because of their intricacy and precision needs. The use of blockchain for enhancing supply chain transparency and digital twins for modelling QA processes is also examined, highlighting creative solutions to modern issues. The integration of these technologies can transform QA procedures by providing unmatched precision and swiftness. Although risk management tools have greatly enhanced QA processes, issues like elevated implementation expenses, absence of unified global standards, and workforce preparedness continue to exist. This document highlights these shortcomings and offers practical suggestions for remedying them, such as promoting a culture of risk awareness and utilizing advanced training resources like virtual reality simulations. The conversation encompasses future trends like continuous manufacturing, sustainable practices, and regulatory updates, highlighting their enduring effects on economic efficiency, public trust, and innovation within the pharmaceutical sector. By implementing sophisticated risk management techniques and strategies, the sector can secure compliance, improve product quality, and establish a strong base for tackling future challenges.

***Corresponding Author:** Balli Rathod
Address: *Samarth Institute of Pharmacy, Belhe*
Email ✉: ballirathod1@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

A systematic method for assessing, controlling, discussing, and looking into threats to the quality of pharmaceutical goods during the course of their lifecycle is called quality risk management, or QRM. It guarantees that risk assessments are grounded in scientific understanding and that the effort invested in the QRM process aligns with the degree of risk.[1]

Adopting QRM in the pharmaceutical sector is essential for ensuring informed, data-driven choices that emphasize the safety of consumers. It enhances resource distribution and promotes a culture of trust and openness among businesses and regulatory bodies.[2]

In the pharmaceutical sector, assessing and managing risks is essential for guaranteeing the safety and effectiveness of products. By actively recognizing and addressing potential risks, companies can avoid quality problems that could result in recalls, regulatory interventions, or harm to patients. This method is in accordance with the expectations of regulatory agencies such as the FDA and EMA, which support risk-based quality management.[3]

Establishing a strong Quality Risk Management (QRM) framework allows pharmaceutical firms to make informed, data-based choices, emphasize consumer safety, and effectively distribute resources according to risk levels. This not only aids in adhering to Good Distribution Practice (GDP) standards but also encourages a climate of openness and trust between companies and authorities. Furthermore, QRM is crucial for preserving medicine quality across the supply chain, as it encompasses organized risk assessment, management, communication, and evaluation. By following QRM principles, pharmaceutical firms can improve their quality assurance practices, ultimately guaranteeing that patients obtain safe and effective products.[4]

Objective and Scope of paper:

This review seeks to deliver an in-depth examination of risk assessment and management tools applied in Quality Assurance (QA) in the pharmaceutical sector. It investigates conventional methods like Failure Mode and Effects Analysis Hazard Analysis and Critical Control Points (HACCP) and Hazard Management Evaluation (FMEA) along with modern technology including blockchain, the Internet of Things (IoT), machine learning (ML), and artificial intelligence (AI). The range includes applications in pharmaceutical production, biotechnology, personalized healthcare, and supply chain management.

Fundamentals of Risk Assessment and Management

Definitions and Concepts

Risk

Risk is the blend of the probability of a negative event taking place and the seriousness of its outcomes. In Quality Assurance (QA), evaluating risk is crucial to comprehend the likelihood of failure in a process, product, or system and how it affects patient safety and quality. Risk is measured by assessing the likelihood of an event happening and the extent of the damage it could inflict. This assessment aids in ranking risks needing action and in determining the extent of control measures required.[5]

Hazard

A hazard is a possible origin of injury or negative impact. In QA, a hazard denotes any element that could lead to a negative result if not adequately managed, like a faulty ingredient, a breakdown in machinery, or a human mistake during the production process. Hazards serve as the foundation for risk evaluation. Recognizing hazards enables businesses to evaluate the related

risks and implement steps to either remove or lessen them. The aim is to stop hazards from turning into real risks.[6]

Risk Control

Risk management involves the measures and tactics employed to reduce or remove recognized risks. It encompasses both preventive and corrective strategies aimed at decreasing the chances of a risk event and/or lessening its effects if it happens. Risk control is an essential component of the risk management process. It encompasses different techniques, such as re-engineering procedures, enhancing processes, utilizing safety gear, and developing backup plans. Risk management strategies rely on the findings of a comprehensive risk evaluation and are crucial for maintaining product quality and ensuring patient safety.[7]

Principle:

When it comes to the pharmaceutical industry, Quality Risk Management (QRM) serves as a structured method for identifying, Evaluating, managing, conveying, and reassessing Risks during the product lifecycle. This procedure guarantees that quality is integrated into products and processes from the beginning, in accordance with the concepts of QbD stands for Quality by Design. The International Harmonization Council (ICH) offers thorough guidelines on QRM, highlighting the significance of scientific understanding and the proportional alignment of risk management activities with the degree of risk.

ICH Q9 Quality Risk Management guidelines:

1) **Scientific Knowledge**: Consumer protection should be the ultimate goal of quality risk assessment, which should be grounded in scientific knowledge such as data and research.
2) **Proportionality**: The degree of risk should be reflected in the amount of work, formality, and paperwork required.
3) **Risk Assessment**: Risk analysis, risk evaluation, and hazard identification are all steps in the process.
4) **Risk Control**: Measures To mitigate Identified Risks should be implemented, considering the benefits, costs, and risk reduction.
5) **Risk Communication**: Open communication among stakeholders is necessary to guarantee that risk information is communicated and comprehended.
6) **Risk Review**: To make sure controls continue to be effective and to find new risks, risks must be continuously monitored and reviewed.

These principles direct the implementation of QRM in different areas of pharmaceutical quality, such as development, manufacturing, distribution, and inspection. For a thorough grasp of these principles and their implementation, consult the ICH Q9 Quality Risk Management guideline.[8]

Overview of guidelines:

Quality risk management (QRM) is an essential element of pharmaceutical quality assurance, guaranteeing that threats to product quality are consistently recognized, assessed, and managed throughout the entire product lifecycle. The International Council for Harmonisation (ICH) has issued detailed guidelines to uniform QRM practices worldwide. Significantly, the for QRM, the ICH Q9 guideline offers a methodical structure. highlighting the significance of risk evaluation, management, communication, and reassessment. The Food and Drug Administration (FDA) of the United States has embraced the ICH Q9 guideline, strengthening its implementation in the pharmaceutical sector. The FDA's guidance document, "Q9(R1) Quality Risk Management," details principles and tool examples for QRM

applicable to multiple facets of pharmaceutical quality, such as development, production, distribution, and the inspection and submission/review procedures.[9]

Likewise, the World Health Organization (WHO) highlights the importance of QRM in its recommendations, promoting a structured approach for evaluating, managing, conveying, and revisiting risks regarding the quality of pharmaceutical products throughout their lifecycle. These coordinated guidelines seek to improve product quality and patient safety by encouraging a proactive stance on risk management within the pharmaceutical industry.[10]

Lifecycle Approach in Risk Management:

Integrating risk management across the pharmaceutical product lifecycle is crucial for maintaining product quality and safeguarding patient safety. The International Council for Harmonisation (ICH) issues guidelines like ICH Q9, which present principles and tools for quality risk management relevant throughout different phases of a product's lifecycle.[11]

Using a lifecycle approach means incorporating risk management practices from the early phases of product development all the way to commercialization and post-market efforts. This ongoing application aids in recognizing potential risks promptly, enabling proactive mitigation strategies, and upholding compliance with regulatory standards. This method not only improves product quality but also aids in operational efficiency and regulatory adherence during the product's entire lifespan.[12]

1 Risk Assessment Tools

FMEA

Failure Modes and Effects Analysis (FMEA) is a well-recognized Quality Risk Management (QRM) instrument used in the pharmaceutical sector. Its power is in methodically pinpointing possible failures in procedures or products prior to their occurrence, enabling the execution of suitable risk reduction strategies to avert or lessen these failures.

HACCP

Hazard Analysis and Critical Control Points (HACCP) is a vital instrument, especially useful for recognizing and managing possible risks in the production processes of food and pharmaceuticals. It concentrates on crucial areas where the chances of contamination or quality failures are most significant, guaranteeing product safety and adherence to standards.

FTA

Fault Tree Analysis (FTA) is used to examine the likelihood of system failures by charting different possible faults within a process. This analytical, top-down method aids in identifying the underlying reasons for failures, enabling focused risk reduction strategies. Risk matrices are used to assess and prioritize risks by evaluating the probability and impact of possible negative occurrences. They offer a visual depiction that assists in decision-making activities, guaranteeing that resources are distributed to tackle the most critical risks.[13]

Examples of Their Application in QA

In pharmaceutical Quality Assurance (QA), these instruments are essential for upholding product quality and ensuring patient safety. FMEA is utilized for equipment and facilities to examine the effects of manufacturing procedures on the quality of products, revealing weaknesses that may result in failures. HACCP is utilized to evaluate systems, guaranteeing that essential control points in the production process are observed and upheld to avoid quality problems. For example, utilizing

FMEA to evaluate HACCP systems can improve the detection of potential non-conformities, thus reinforcing the entire QA process.

Risk Management Techniques

Communication, Documentation, and Decision-Making Frameworks

Successful risk management in QA depends significantly on strong communication, comprehensive documentation, and organized decision-making processes. Quality Risk Management (QRM) is a structured approach to evaluating, managing, conveying, and examining risks that could impact the quality of products or services. The idea of QRM is derived from ICH Q9, a guideline created by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Communication guarantees that all parties understand potential risks and the strategies implemented to alleviate them. Documentation offers a comprehensive account of risk evaluations and management choices, promoting transparency and adherence to regulatory requirements. Decision-making frameworks assist in assessing risks and identifying suitable control strategies, making certain that decisions are coherent, justified, and in line with organizational goals.[14]

Advanced Tools and Technologies

Predictive Analytics, AI, and ML for Proactive Risk Management

The combination of predictive analytics, Machine learning (ML) and artificial intelligence (AI) are revolutionizing risk management in QA by facilitating the proactive detection and resolution of potential problems. Predictive analytics utilizes sophisticated statistical methods and machine learning algorithms to examine past and current data, identify patterns, and forecast future results.[15]

AI and ML improve this process by persistently learning from data, thus enhancing prediction accuracy as time progresses. In the realm of IT change management, for instance, predictive AI can examine past change data to pinpoint trends that commonly result in failures or disruptions, enabling IT teams to implement proactive strategies to reduce these risks.[16]

In the pharmaceutical sector, these technologies can be utilized to oversee production procedures in real-time, identify irregularities that could signal developing risks, and recommend ideal interventions. Utilizing AI, deep learning, and ML allows businesses to proactively detect compliance violations, foresee regulatory shifts, and improve decision-making strategies, thus enhancing overall quality assurance.[17]



2 AI and Machine Learning in Risk Assessment

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing risk evaluation in pharmaceutical Quality Assurance (QA) by facilitating the early detection and prevention of potential problems. AI algorithms examine extensive datasets from production methods, quality management, and incident reports to identify irregularities and forecast potential risks. This method enables timely intervention, lowering the chances of product recalls and safeguarding patient safety. For example, AI is capable of examining 'slight' variations to detect patterns, facilitating more targeted inquiries into important matters.[18]

Digital Twins in Risk Management

Digital twin technology consists of generating virtual duplicates of physical assets, processes, or systems. In the production of pharmaceuticals, digital twins replicate manufacturing processes to anticipate failures and enhance operations. Through the incorporation of real-time data, digital twins facilitate proactive measures, minimizing downtime and improving productivity. For instance, GlaxoSmithKline (GSK) has employed digital twin technology to enhance its production of vaccine adjuvants, resulting in more efficient manufacturing methods.[19]

Internet of Things (IoT) and QA

IoT, or the Internet of Things links devices and systems, enabling real-time oversight in pharmaceutical quality assurance. Sensors equipped with IoT technology gather data from different phases of the manufacturing process, offering insights into machinery performance, environmental factors, and product quality. This connectivity enables prompt corrective measures when quality standard deviations are identified, thus lowering the chances of product recalls and maintaining patient safety.[20]

3 Supply Chain Vulnerabilities

Risk Assessment for Raw Material Sourcing and Supplier Quality

Pharmaceutical supply chains are prone to several weaknesses, especially regarding the procurement of raw materials and the reliability of suppliers. Recognizing and measuring these risks is crucial to guarantee the continuous provision of medications. Elements like exclusive or restricted suppliers, the geographical concentration of producers, and political or geopolitical risks can greatly influence the stability of the supply chain. For example, depending too much on one supplier or area might result in shortages during disruptions. Adopting strong risk assessment methods aids in proactively tackling these issues, thereby improving the resilience of the pharmaceutical supply chain.[21]

Impact of Global Disruptions (e.g., Pandemics, Geopolitical Issues) on QA

Worldwide disturbances, including pandemics and geopolitical conflicts, can significantly impact pharmaceutical supply chains, resulting in shortages and quality assurance (QA) issues. For example, the COVID-19 epidemic shown how vulnerable global supply lines are resulting in delays and shortages of vital medications. Likewise, geopolitical conflicts may lead to trade limitations, impacting the supply of raw materials and completed goods. These interruptions highlight the necessity for pharmaceutical companies to create contingency strategies and broaden their supply sources to uphold consistent quality assurance standards and guarantee patient safety.[22]



Blockchain Technology

Blockchain for Transparency and Traceability in Supply Chains

Blockchain technology presents a hopeful approach to improving transparency and traceability in pharmaceutical supply chains. Through a decentralized and unchangeable ledger, blockchain allows all parties to obtain real-time information about the flow and condition of pharmaceutical products. This clarity aids in confirming the legitimacy of medications, minimizing the chance of fake drugs infiltrating the market, and guaranteeing adherence to quality benchmarks. Moreover, blockchain can simplify administrative tasks, minimize mistakes, and enhance overall efficiency in the supply chain.[23]

Case Studies of Blockchain Implementation for Reducing QA Risks

Various case studies have shown the efficacy of blockchain in reducing QA risks in pharmaceutical supply chains. For instance, research suggested a blockchain-driven solution to guarantee the secure and traceable distribution of medications from start to finish. This system was designed to tackle problems like counterfeit medications and fragmented data by offering a transparent and secure platform for monitoring pharmaceutical products across the supply chain. Applying these blockchain solutions has demonstrated potential in boosting data integrity, enhancing traceability, and meeting regulatory requirements, consequently lowering QA risks.[24]



4 Future Perspectives

Continuous Manufacturing and QA

Continuous manufacturing, a developing trend in drug production, provides the ability for immediate quality control and risk management. Through the incorporation of real-time oversight

and predictive analysis, manufacturers can evaluate risks throughout the production cycle and proactively modify parameters to uphold product quality. This active method minimizes variability, guarantees uniformity, and facilitates quicker detection of possible problems, thus improving overall product quality and lowering the risk of non-compliance. Recent research emphasizes the importance of automated systems and sensors in facilitating ongoing process verification, which promotes smooth and effective risk management in manufacturing settings.

Sustainability in Risk Management

Sustainability in the pharmaceutical sector is becoming progressively crucial as firms implement more eco-friendly methods in production. Environmental risk management is currently incorporated into Quality Assurance (QA) practices, emphasizing waste reduction, energy consumption decrease, and the use of sustainable materials in manufacturing processes. Eco-friendly manufacturing approaches, including renewable energy utilization, waste minimization, and sustainable packaging, are emerging as crucial elements in quality assurance, helping to reduce the environmental effects of pharmaceutical production. Moreover, implementing sustainable practices in risk management not only aids in achieving regulatory compliance but also enhances brand reputation and promotes a more environmentally aware mindset within the industry.

Workforce Training and Risk Culture

Cultivating a risk-aware culture in pharmaceutical companies is crucial for effectively managing quality-related risks. Well-designed training initiatives that concentrate on fostering a robust risk management mentality enable employees across all tiers to recognize and react to possible risks. Sophisticated training instruments, such as virtual reality (VR) and simulations, deliver an engaging educational experience, enabling employees to replicate real-world risk situations and grasp the outcomes of their choices. By integrating interactive technologies into training, organizations can enhance their employees' readiness to manage complex risk scenarios, promoting a more proactive stance on quality assurance. Moreover, nurturing a culture that prioritizes ongoing learning and adjustment to new risks enhances the overall effectiveness of the quality management system.

Challenges and limitation:

1. Barriers to Implementing Risk Management Tools

The pharmaceutical industry encounters multiple challenges when implementing risk management tools. A major obstacle is the presence of organizational silos and dependence on manual processes and spreadsheets in the absence of a structured risk framework. This disconnection results in incorrect risk information and obstructs efficient risk management.[25]

2. Gaps in Traditional Methods and Emerging Needs

Conventional risk management approaches in the pharmaceutical sector frequently have weak methodological frameworks, resulting in deficiencies in assessing the efficacy of risk reduction measures. This shortcoming highlights the necessity for more organized and scientifically sound methods for risk evaluation and management.[26]

CONCLUSION

In summary, risk assessment and management are essential components in upholding high standards of Quality Assurance (QA) in the pharmaceutical

sector. The combination of conventional tools like Failure Mode and Effects Analysis (FMEA) and Hazard Analysis and Critical Control Points (HACCP) persists in providing organized and methodical strategies for reducing risks. Nonetheless, the swiftly changing technological environment has brought about fresh opportunities to improve risk management practices. New technologies like the Internet of Things (IoT), machine learning (ML), and artificial intelligence (AI) are becoming crucial in preemptive risk assessment and decision-making, providing real-time information that aids in ensuring product quality and regulatory compliance.

In the future, continuous manufacturing offers a major chance for real-time management of production risks, enhancing efficiency and decreasing product variability. Moreover, incorporating sustainability practices into risk management, like eco-friendly manufacturing and waste reduction, demonstrates the industry's dedication to environmental accountability while upholding high-quality standards. Training initiatives aimed at fostering a risk-conscious culture, along with cutting-edge resources such as virtual reality (VR) and simulations, provide an engaging method for equipping the workforce to handle new risks

REFERENCES

1. International Conference on Harmonisation (ICH). Guideline Q9: Quality Risk Management. European Medicines Agency. Available at: https://www.ema.europa.eu
2. SafetyCulture. Quality Risk Management: A Guide to Understanding QRM. Available at: https://safetyculture.com
3. Risk Assessment in Pharma Quality Assurance Careers." NeuAge Institute. Available at: https://neuageinstitute.com/blogs/risk-assessment-in-pharma-quality-assurancecareers.
4. Quality Risk Management (QRM): What it is and How to Implement." Safety Culture. Available at: https://safetyculture.com/topics/quality-risk-management
5. U.S. Food and Drug Administration. (2005). Risk management guide for pharmaceutical manufacturers. U.S. Food and Drug Administration. https://www.fda.gov/media/70742/downloa
6. U.S. Food and Drug Administration. (2005). Risk management guide for pharmaceutical manufacturers. U.S. Food and Drug Administration. https://www.fda.gov/media/70742/download
7. U.S. Food and Drug Administration. (2005). Risk management guide for pharmaceutical manufacturers. U.S. Food and Drug Administration. https://www.fda.gov/media/70742/download
8. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2005). Q9 Quality Risk Management [Guideline]. Retrieved from https://database.ich.org/sites/default/files/Q9_Guideline.pdf
9. International Council for Harmonisation (ICH). ICH Q9: Quality Risk Management. Published by ICH Secretariat, 2005. Available at: https://www.ich.org/page/quality-guidelines
10. World Health Organization (WHO). WHO Guidelines on Quality Risk Management. Available at: https://www.who.int
11. International Council for Harmonisation (ICH). (2005). ICH Q9: Quality Risk Management. Retrieved from https://database.ich.org/sites/default/files/Q9_Guideline.pdf
12. ValGenesis. (n.d.). Quality Risk Management in the Lifecycle Approach. Retrieved from

https://www.valgenesis.com/blog/qrm-lifecycle-management

13. Ingaldi, M., & Kaczmarek, M. K. (2021). Application of Failure Mode and Effect Analysis (FMEA) for audit of HACCP system. Management Systems in Production Engineering, 29(1), 1-6. https://doi.org/10.2478/mspe-2021-0001
14. TRDSF. (2023, November 27). Quality risk management in the pharmaceutical industry. TRDSF. https://trdsf.com/blogs/news/quality-risk-management
15. ResearchGate - Predictive Analytics and AI Driving the Next Wave of Risk Management in Financial Services https://www.researchgate.net/publication/383498803_Predictive_Analytics_and_AI_Driving_the_Next_Wave_of_Risk_Management_in_Financial_Services
16. Accrete AI - Using Predictive AI for Proactive Risk Assessment in IT Change Management https://www.accrete.ai/blog/using-predictive-ai-for-proactive-risk-assessment-in-it-change-management
17. Rupp, M. (2024, January 13). Leveraging AI and predictive analytics for success in information management. Big Data Quarterly. https://www.dbta.com/BigDataQuarterly/Articles/Leveraging-AI-and-Predictive-Analytics-for-Success-in-Information-Management-167346.aspx
18. Birse M. Use of AI in Pharmaceutical Quality and Operations [Internet]. Parexel International; 2024 [cited 2025 Jan 15]. Available from: https://www.ipa-india.org/wp-content/uploads/2024/06/Use-of-AI-in-Pharmaceutical-Quality-and-Operations-Mark-Birse-Vice-President-Technical-Strategic-Compliance-Consulting-Parexel-International.pdf
19. Nobis S. Digital twins as a key player in pharmaceutical production [Internet]. COPA-DATA; 2025 Jan [cited 2025 Jan 15]. Available from: https://blog.copadata.com/digital-twins-as-a-key-player-in-pharmaceutical-production
20. Supply Chain Wizard. (n.d.). Digital twins for pharma: Your virtual blueprint for a more efficient and resilient supply chain. Retrieved from https://supplychainwizard.com/digital-twins-for-pharma-your-virtual-blueprint-for-a-more-efficient-and-resilient-supply-chain/
21. U.S. Pharmacopeia. (2024). Identifying and addressing vulnerabilities in the upstream medicines supply chain to build resilience and reduce drug shortages. Retrieved from https://www.usp.org/sites/default/files/usp/document/public-policy/supply-chain-resilience-policy-paper.pdf
22. U.S. Department of Health and Human Services. (2024). Policy considerations to prevent drug shortages and mitigate supply chain vulnerabilities in the United States. Retrieved from https://aspe.hhs.gov/reports/preventing-shortages-supply-chain-vulnerabilities
23. Qualifyze. (2023, August 28). The role of blockchain technology in pharma. Retrieved from https://www.qualifyze.com/resources/blog/the-role-of-blockchain-technology-in-pharma
24. Kumar, A. K. R. G. N., & Krishna, G. S. S. G. (2020). Blockchain & IoT based drugs traceability for pharma industry. IEEE. https://ieeexplore.ieee.org/document/9570251/?utm_source=chatgpt.com
25. Camms Group. (2023). Managing risk in the pharmaceutical & life sciences sector. Camms. https://cammsgroup.com/blog/managing-risk-in-the-pharmaceutical-sector/
26. Amenta, V., Molinari, A., & Celia, C. (2014). Risk management in the pharmaceutical industry: Key challenges and opportunities.

BMC Health Services Research, 14(1), 1-9. https://pubmed.ncbi.nlm.nih.gov/24616240/

HOW TO CITE: Balli Rathod, Harshal Navale, Dr. Sachin Datkhile, Risk Assessment and Management Tools in QA, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 4594-4604. https://doi.org/10.5281/zenodo.15537538